Cytori is committed to developing and commercializing specialty therapeutics. Since 2002, Cytori has enabled researchers and clinicians to study and administer cell therapies using our novel Celution® System platform which harnesses the potential of stem and regenerative cells from adipose tissue. In 2017, Cytori strengthened its specialty therapeutics position by acquiring a nanomedicine platform technology that combines widely-known and prescribed chemotherapy agents, doxorubicin and docetaxel, both with liposomal encapsulation technology. This marriage of technologies has the potential to improve patient care for both life-debilitating and life-threatening conditions and diseases.
Cytori Therapeutics, Inc. is dedicated to enhancing lives through the development of novel therapeutics. To realize this mission, Cytori defines, develops, and delivers specialty therapeutics that address poorly met market and medical needs. Through constantly balancing a blend of creativity, rigor, focused energy, and agility, we strive to deliver meaningful results that create exceptional value for patients, customers, partners, employees, shareholders, and society.
- We do what is right, deliver what we promise and own the outcome.
- We place our patients and customers at the heart of everything we do.
- We thoughtfully balance competing priorities to achieve important results.
- We are an agile company that embraces big challenges.
- We value spirited communication and care about one another.
At the end of 2018, Cytori had 37 full-time employees based in the United States and Japan, with 21 engaged in research and development. Many of these employees hold advanced PhD and MD degrees from top universities. Cytori plans to grow its organization, particularly in its San Antonio location, in support of its nanomedicine program.
In 2013, Cytori granted Bimini Technologies a global exclusive license to Cytori Cell Therapy technology for hair applications. Through Kerastem, its wholly owned subsidiary, Bimini Technologies is conducting a FDA-approved, 70 patient, Phase II clinical trial in the U.S. called STYLE. Learn about the 6 month top-line results released in December 2017 here.
In 2013, Cytori granted Lorem Vascular a 30-year exclusive license to Cytori Cell Therapy technology for all clinical indications (except hair applications) for the territories of Australia, China, Hong Kong, Malaysia, and Singapore. In 2015, Cytori and Lorem Vascular announced that China FDA had granted regulatory clearance for the Cytori Celution® System.
For parties interested in licensing Cytori Cell Therapy™ or Cytori Nanomedicine™ technologies, please contact us at BusinessDevelopment@cytori.com.